Substandard anti-malarial drugs in Burkina Faso
Open Access
- 27 May 2008
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 7 (1) , 95
- https://doi.org/10.1186/1475-2875-7-95
Abstract
There is concern about an increasing infiltration of markets by substandard and fake medications against life-threatening diseases in developing countries. This is particularly worrying with regard to the increasing resistance development of Plasmodium falciparum against affordable anti-malarial medications, which has led to a change to more expensive drugs in most endemic countries.Keywords
This publication has 28 references indexed in Scilit:
- Antimalarial drug quality in AfricaJournal of Clinical Pharmacy & Therapeutics, 2007
- The Great Failure of Malaria Control in Africa: A District Perspective from Burkina FasoPLoS Medicine, 2007
- Counterfeit or substandard antimicrobial drugs: a review of the scientific evidenceJournal of Antimicrobial Chemotherapy, 2007
- The Hunt for Counterfeit MedicineAnalytical Chemistry, 2007
- Quality evaluation of chloroquine, quinine, sulfadoxine?pyrimethamine and proguanil formulations sold on the market in East Congo DRJournal of Clinical Pharmacy & Therapeutics, 2007
- Quality control of active ingredients in artemisinin‐derivative antimalarials within Kenya and DR CongoTropical Medicine & International Health, 2006
- Manslaughter by Fake Artesunate in Asia—Will Africa Be Next?PLoS Medicine, 2006
- The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sectorJournal of Clinical Pharmacy & Therapeutics, 2005
- Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam TanzaniaJournal of Clinical Pharmacy & Therapeutics, 2003
- Low-Cost Quality Assurance of Medicines Using the Gphf-Minilab®Drug Information Journal, 2001